Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Sep 9;22(27-28):3809-15.
doi: 10.1016/j.vaccine.2003.06.003.

T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19

Affiliations

T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19

Rauli Franssila et al. Vaccine. .

Abstract

Recombinantly expressed virus-like particles of human parvovirus B19 containing the two structural proteins VP1 and VP2 (VP1/2 capsids) or VP2 alone (VP2 capsids) elicit vigorous antibody responses in animal models, whereas only VP1/2 capsids elicit neutralizing antibodies. VP1 is, therefore, essential for protective B-cell immunity. In this study, we determined the ability of VP1/2 capsids containing VP1 and VP2 in the ratio recommended for vaccine use, and of sole VP2 capsids to stimulate T-helper (Th) cells to proliferate and to secrete interferon gamma (IF-gamma) and interleukin-10 (IL-10) in humans long after natural infection. Similar proliferation, IF-gamma and IL-10 responses were found with the VP1/2 and VP2 capsids. We conclude that, whereas VP1 contains important B-cell epitopes, VP2, the major structural protein of human parvovirus B19, appears to provide the major target for B19-specific Th-cells years or decades after natural infection.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources